For many young scientists, a PhD is the beginning of an international career.The next step is often predictable: a prestigious research fellowship, a postdoctoral position abroad, publications in leading journals and, eventually, a faculty position.Dr Parul Ganju had those opportunities.She had earned a PhD in Skin Biology from the National Institute of Immunology (NII), New Delhi. She had a government research fellowship within reach. A postdoctoral position in the United States was also on the table.But during her doctoral research, something happened that changed her definition of success.She began meeting people living with vitiligo—a chronic autoimmune condition in which the body’s immune system destroys pigment-producing cells, leaving white patches on the skin. In India, where appearance often influences confidence, relationships and even career opportunities, she realised the disease affected far more than skin.
Why Dr Parul Ganju turned down a US opportunity to pursue a vitiligo treatment. (Photo: LinkedIn)
“The effect of this disease was humongous,” she would later recall. “People were waiting for something to work.”That question stayed with her long after her PhD ended.Instead of asking where her career would take her, she began asking something else.Who was actually building a cure?
When patients changed the direction of a scientist’s career
Dr Ganju had spent years studying skin biology, but interacting with patients gave her research a new purpose.She realised that despite decades of scientific progress, treatment options for vitiligo remained limited.The commonly prescribed medicines, particularly steroids, often suppress the body’s immune system broadly to slow the disease. While they may help some patients, they do not permanently stop the disease, cannot restore lost pigmentation in many cases and may lead to significant side effects when used for long periods.For millions of people living with vitiligo, there was still no treatment that directly targeted the root cause of the disease.Instead of accepting that reality, she decided to work on changing it.
She walked away from a comfortable career to build a biotech startup
In 2016, Dr Parul Ganju co-founded Ahammune Biosciences in Pune with her PhD collaborator Dr Krishnamurthy Natarajan, a professor at Jawaharlal Nehru University (JNU).It was an unconventional decision.Building a biotechnology company meant years of uncertainty, fundraising, failed experiments and long clinical trials.Yet she believed that publishing another research paper would not immediately improve a patient’s life.Developing a medicine might.The company’s lead drug candidate, AB1001, is designed to work differently from existing treatments.Rather than suppressing the body’s immune system broadly, it aims to block the specific cellular signalling pathway responsible for destroying melanocytes—the pigment-producing cells affected in vitiligo.Dr Ganju has described the approach simply as “cutting fuel to the fire.”Today, AB1001 has successfully completed Phase 1 clinical trials and has advanced to Phase 2, bringing it one step closer to potentially becoming a new treatment option.The company has also secured patents across multiple countries and raised around 8 million US dollars from investors including pi Ventures, Ideaspring Capital and Kotak Alternate Assets.
Why her story matters on World Allergy Day
Today, July 8, is observed globally as World Allergy Day, a reminder of the growing impact of immune-related disorders and the importance of advancing research into conditions driven by the immune system.While vitiligo is not classified as an allergy, it is an autoimmune disease, where the immune system mistakenly attacks healthy cells in the body.The observance offers an opportunity to appreciate the scientists working to better understand immune disorders and develop targeted therapies that improve patients’ lives.It also aligns with a broader message celebrated through initiatives such as National Love Your Skin Day — that healthy skin is about far more than appearance. It is about confidence, well-being and quality of life.
Sometimes the biggest career decision isn’t about where you go—it’s about why you stay
For students, Dr Parul Ganju’s journey offers a different way to think about success.Many graduates dream of overseas research positions, prestigious fellowships and international careers.There is nothing wrong with those ambitions.But her story shows that sometimes the biggest impact comes from choosing a harder path—one driven by purpose rather than prestige.Millions of people worldwide continue to live with vitiligo, and India has one of the largest patient populations.Whether AB1001 eventually becomes a widely available treatment will depend on the outcome of ongoing clinical trials and regulatory approvals.But one thing is already clear.A scientist who could have spent her career publishing papers chose instead to spend it solving a problem that patients had lived with for decades.And sometimes, that’s the kind of research that changes lives.Disclaimer: This article is based on publicly available information about Dr Parul Ganju, Ahammune Biosciences and the company’s ongoing clinical research. References to AB1001 relate to its current stage of clinical development. The drug remains under investigation and has not yet received regulatory approval for general clinical use. The article is intended for informational and educational purposes only and should not be considered medical advice.